Giao diện
TeguNews
Thế giới

NITI Aayog proposes ₹50,000 crore fund to make India global biotech power

NITI Aayog roadmap proposes adoption of a mission-mode execution strategy backed by new financing and regulatory reforms, targets expanding India’s bioeconomy from $195.3 billion in 2025 to $2.6 trillion by 2047

The Hindu3 phút đọc

NITI Aayog proposes ₹50,000 crore fund to make India global biotech power

A NITI Aayog roadmap has proposed creating a ₹50,000 crore BioEconomy Growth Fund, a dedicated production-linked incentive (PLI) scheme for biomanufacturing and six national biotechnology missions as part of an ambitious strategy to transform India into one of the world’s top three biotechnology powers by 2035.The report, Roadmap for Building India as a Leading BioEconomy Powerhouse by 2035, was made public on Thursday (July 16, 2026). It says India should move beyond the broad framework laid out under the Biotechnology for Economy, Environment and Employment (BioE3) policy and adopt a mission-mode execution strategy backed by new financing, regulatory reforms and cross-ministerial governance.

It targets expanding India’s bioeconomy from $195.3 billion in 2025 to $691 billion by 2035 and $2.6 trillion by 2047, while generating more than 30 million high-value jobs.

India's bioeconomy sector to reach $300 billion by 2030: NITI Aayog report“The goal is not to just research but to build globally competitive biotechnology companies,” said Debjani Ghosh, Distinguished Fellow, NITI Aayog, at the launch of the report.The centrepiece of the recommendations is a proposed ₹50,000 crore fund for 2026-35 to bridge what the report describes as the biotechnology sector’s “valley of death” — the gap between proof-of-concept research and commercial-scale manufacturing. The fund would provide blended finance, equity-risk instruments, viability-gap funding and infrastructure support for biomanufacturing, advanced therapeutics, synthetic biology, fermentation technologies and diagnostics.

It also recommends introducing a dedicated PLI scheme for biomanufacturing to accelerate domestic production and reduce import dependence.The roadmap also recommends launching six National BioMissions with clearly identified lead Ministries and measurable outcomes by 2035. These include GeneIndia for affordable gene and cell therapies, AgriBio 2.

0 for climate-resilient gene-edited crops and biological farm inputs, BioX Foundry to commercialise synthetic biology innovations, One Health Grid for integrated surveillance of infectious diseases and antimicrobial resistance, Marine Biotechnology to expand seaweed cultivation and marine bio-products, and BioPharmaNext to establish India as a global hub for biologics, biosimilars and AI-enabled drug discovery.To coordinate implementation, the report proposes creating several new institutions, including an Empowered Committee on National BioMissions, a National BioData Council to oversee biological and health data governance, a BioEconomy Investment and Policy Forum to align government and private investment, and a BioIP and Innovation Evaluation Agency to help value biotechnology intellectual property and accelerate commercialisation.“We need to improve data sharing particularly among Ministries,” said Soumya Swaminathan, Chairperson, MS Swaminathan Research Foundation, and one of the advisors on the report.

“We have a 10,000-genome project but the UK Bio Bank has 50,000 genomes all matched with clinical endpoints. This has led to tens of thousands of highly cited research papers being generated.”The roadmap further recommends dedicated fast-track approval pathways for emerging technologies such as cell and gene therapies, synthetic biology and AI-designed drugs, alongside modernisation of the Central Drugs Standard Control Organisation.

It also calls for five integrated bio-innovation clusters with shared manufacturing facilities and high-performance computing centres under the National Supercomputing Mission to support AI-driven drug discovery and computational biology.More broadly, the report argues that biotechnology should be treated as national infrastructure on par with digital public infrastructure and energy systems. It says India’s next phase of growth will depend on integrating artificial intelligence, robotics, computational biology and automated biofoundries to shorten research timelines and build globally competitive biomanufacturing capabilities.

The roadmap was prepared by NITI Aayog’s Frontier Tech Hub in consultation with industry and academic experts, with contributions from the Department of Biotechnology. Published - July 16, 2026 09:43 pm IST Read Comments Copy link Email Facebook Twitter Telegram LinkedIn WhatsApp Reddit READ LATER SEE ALL Remove Related Topics science (general)

Nguồn: The Hindu

Đọc thêm từ Thế giới

Thế giới

【まとめてわかる】全台使用中止の万博EVバス、何が問題なのか?

有料記事 大阪・関西万博の会場などで使われた電気自動車(EV)バス190台すべてが使用中止になった問題をめぐり、大阪メトロは16日、経営責任を問い、役員らの処分を発表する。どのような経緯でこのような事態になり、何が問題なのでしょうか。 (1)どんなバスなのか(2)なぜ使用中止を決めたのか(3)なぜEVMJから購入したのか(4)何が問題なのか(5)今後の課題は 大阪メトロは2022~24年度、「EVモーターズジャパン」(EVMJ)から190台を購入した。EVMJは19年に設立された新興企業で、本社は北九州市にあるが、バスを中国メーカーに委託して製造・輸入し

Asahi Shimbun